# Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults

> **NCT00002427** · PHASE1 · COMPLETED · sponsor: **Research Institute for Genetic and Human Therapy** · enrollment: 225 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Hydroxyurea
- **DRUG:** Stavudine
- **DRUG:** Didanosine

## Key facts

- **NCT ID:** NCT00002427
- **Lead sponsor:** Research Institute for Genetic and Human Therapy
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 225 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002427, "Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*